Vaira Valentina

Junior Principal Investigator

 

Bio

Valentina Vaira graduated from Milan University Faculty of Veterinary Biotechnologies in 2002 and received her Ph.D degree in Molecular Oncology in 2006. From 2010 to 2013 she collaborated as a post-Doc fellow at the Division of Pathology of Fondazione IRCCS Ca’ Granda with Profs. Silvano Bosari and Stefano Ferrero on microRNA deregulation in human carcingenesis. As part of her training, she spent time in foreign academic research centers such as University of Massachusetts Medical School, Harvard University – Dana Farber Cancer Institute, and The Wistar Institute, to acquire knowledge and skills in molecular and cellular biology, transgenic mouse models, and to develop an ex-vivo tissue culture platform suitable for preclinical tests. This training contributed in generating research papers and provided the basis for long-term scientific projects.

 

Projects

Currently, her research interests focus on microRNA deregulation in human carcinogenesis and on the role of vacuolar H+- ATPase (V-ATPase) pump in human glioma.
The project funded by Italian Ministry of Health focuses on the study of common molecular mechanisms that drive the metastatic disease in human lung cancer using a panel of transgenic animal models and human series. This research aims to identify non-coding RNAs profiles in distinct cell subpopulations (epithelial, stromal and the cancer-stem cell niche) to provide valuable prognostic and therapeutic tools for advanced lung cancer patients’ management.
V-ATPase deregulation in human glioma. Preliminary data indicate that levels of V-ATPase expression correlate with aggressiveness and poor prognosis in glioblastoma and inhibition of the pump activity reduces the cancer stem cell population in GBM cells. Based on this background, the project aims to explore the role of V-ATPase overexpression on cancer-relevant processes using a multidisciplinary approach that includes patients’ series, and different in vitro and in vivo models of brain tumorigenesis.

Publications

Role of Strain Rate in the Pathogenesis of Ventilator-Induced Lung Edema
Protti A1, Maraffi T, Milesi M, Votta E, Santini A, Pugni P, Andreis DT, Nicosia F, Zannin E, Gatti S, Vaira V, Ferrero S, Gattinoni L.
Crit Care Med. 2016 Apr 6. [Epub ahead of print]

PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion.
Caino MC, Ghosh JC, Chae YC, Vaira V, Rivadeneira DB, Faversani A, Rampini P, Kossenkov AV, Aird KM, Zhang R, Webster MR, Weeraratna AT, Bosari S, Languino LR, Altieri DC.
Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8638-43. doi: 10.1073/pnas.1500722112

Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression.
Forno I, Ferrero S, Russo MV, Gazzano G, Giangiobbe S, Montanari E, Del Nero A, Rocco B, Albo G, Languino LR, Altieri DC, Vaira V, Bosari S.
PLoS One. 2015 Jun 24;10(6):e0130060.

The vacuolar H+ ATPase is a novel therapeutic target for glioblastoma
Di Cristofori A, Ferrero S, Bertolini I, Gaudioso G, Russo M V, Berno V, Vanini M, Locatelli M, Zavanone M, Rampini P, Vaccari T, Caroli M and Vaira V.
Oncotarget, 5. May, 22, 2015. Advanced online publication.

Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model
Lo Dico A, Martelli C, Valtorta S, Raccagni I, Diceglie C, Belloli S, Gianelli U, Vaira V, Politi LS, Bosari S, Lucignani G, Moresco RM, Ottobrini L.
Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1093-105. doi: 10.1007/s00259-015-3040-7015-3040-7.

A new mouse avatar model of non-small cell lung cancer
Russo MV, Faversani A, Gatti S, Ricca D, Del Gobbo A, Ferrero S, Palleschi A, Vaira V, Bosari S.
Front Oncol. 2015 Mar 3;5:52. doi: 10.3389/fonc.2015.00052. eCollection 2015.

Epigenetic alterations in human parathyroid tumors
Verdelli C, Forno I, Vaira V, Corbetta S.
Endocrine. 2015 Feb 27. [Epub ahead of print]

Epigenetic alterations in cancer and personalized cancer treatment.
Miozzo M, Vaira V, Sirchia SM.
Future Oncol. 2015 Jan;11(2):333-48. doi: 10.2217/fon.14.237.

MicroRNA deregulation in parathyroid tumours suggests an embryonic signature.
Verdelli C, Forno I, Vaira V, Corbetta S.
J Endocrinol Invest. 2015 Jan 11. [Epub ahead of print]

Interferon lambda-3 is not associated with clinical outcome in patients with HCV-induced compensated cirrhosis: A long-term cohort study.
Bruno S, Thompson AJ, Critelli R, Crosignani A, Rossi S, De Lisi S, Cariani E, Zermiani P, Vaira V, Boccaccio V, Maisonneuve P, Villa E.
Antiviral Res. 2015 Jan;113:27-32. doi: 10.1016/j.antiviral.2014.11.002. Epub 2014 Nov 11.

Different expression of protein kinase A (PKA) regulatory subunits in normal and neoplastic thyroid tissues.
Ferrero S, Vaira V, Del Gobbo A, Vicentini L, Bosari S, Beck-Peccoz P, Mantovani G, Spada A, Lania AG.
Histol Histopathol. 2014 Sep 26. [Epub ahead of print]

The oncofetal protein IMP3: a useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung.
Del Gobbo A, Vaira V, Guerini Rocco E, Palleschi A, Bulfamante G, Ricca D, Fiori S, Bosari S, Ferrero S.
J Thorac Oncol. 2014 Nov;9(11):1656-61. doi: 10.1097/JTO.0000000000000316.

MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.
Vaira V, Roncalli M, Carnaghi C, Faversani A, Maggioni M, Augello C, Rimassa L, Pressiani T, Spagnuolo G, Di Tommaso L, Fagiuoli S, Rota Caremoli E, Barberis M, Labianca R, Santoro A, Bosari S.
Liver Int. 2014 Jul 10. doi: 10.1111/liv.12636.

MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma.
Augello C, Gianelli U, Savi F, Moro A, Bonoldi E, Gambacorta M, Vaira V, Baldini L, Bosari S.
J Clin Pathol. 2014 Aug;67(8):697-701. doi: 10.1136/jclinpath-2014-202352. Epub 2014 Jun 9.

Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.
Faversani A, Vaira V, Moro GP, Tosi D, Lopergolo A, Schultz DC, Rivadeneira D, Altieri DC, Bosari S.
Breast Cancer Res. 2014 May 30;16(3):R55. doi: 10.1186/bcr3666.

microRNA profiles in coeliac patients distinguish different clinical phenotypes and are modulated by gliadin peptides in primary duodenal fibroblasts.
Vaira V, Roncoroni L, Barisani D, Gaudioso G, Bosari S, Bulfamante G, Doneda L, Conte D, Tomba C, Bardella MT, Ferrero S, Locatelli M, Elli L.
Clin Sci (Lond). 2014 Mar;126(6):417-23. doi: 10.1042/CS20130248.

Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells.
Caino MC, Chae YC, Vaira V, Ferrero S, Nosotti M, Martin NM, Weeraratna A, O’Connell M, Jernigan D, Fatatis A, Languino LR, Bosari S, Altieri DC.
J Clin Invest. 2013 Jul 1;123(7):2907-20. doi: 10.1172/JCI67841. Epub 2013 Jun 10.

Regulation of lung cancer metastasis by Klf4-Numb-like signaling.
Vaira V, Faversani A, Martin NM, Garlick DS, Ferrero S, Nosotti M, Kissil JL, Bosari S, Altieri DC.
Cancer Res. 2013 Apr 15;73(8):2695-705. doi: 10.1158/0008-5472.CAN-12-4232. Epub 2013 Feb 25.

The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma.
Pinato DJ, Mauri FA, Lloyd T, Vaira V, Casadio C, Boldorini RL, Sharma R.
Br J Cancer. 2013 Feb 19;108(3):621-8. doi: 10.1038/bjc.2013.9. Epub 2013 Jan 29.

Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s.
Chae YC, Caino MC, Lisanti S, Ghosh JC, Dohi T, Danial NN, Villanueva J, Ferrero S, Vaira V, Santambrogio L, Bosari S, Languino LR, Herlyn M, Altieri DC.
Cancer Cell. 2012 Sep 11;22(3):331-44. doi: 10.1016/j.ccr.2012.07.015.

Immunological effects of transglutaminase-treated gluten in coeliac disease.
Elli L, Roncoroni L, Hils M, Pasternack R, Barisani D, Terrani C, Vaira V, Ferrero S, Bardella MT.
Hum Immunol. 2012 Oct;73(10):992-7. doi: 10.1016/j.humimm.2012.07.318. Epub 2012 Jul 23.

The microRNA cluster C19MC is deregulated in parathyroid tumours.
Vaira V, Elli F, Forno I, Guarnieri V, Verdelli C, Ferrero S, Scillitani A, Vicentini L, Cetani F, Mantovani G, Spada A, Bosari S, Corbetta S.
J Mol Endocrinol. 2012 Jul 26;49(2):115-24. Print 2012 Oct.

Chk2 phosphorylation of survivin-DeltaEx3 contributes to a DNA damage-sensing checkpoint in cancer.
Lopergolo A, Tavecchio M, Lisanti S, Ghosh JC, Dohi T, Faversani A, Vaira V, Bosari S, Tanigawa N, Delia D, Kossenkov AV, Showe LC, Altieri DC.
Cancer Res. 2012 Jul 1;72(13):3251-9. doi: 10.1158/0008-5472.CAN-11-4035. Epub 2012 May 14.

MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma.
Augello C, Vaira V, Caruso L, Destro A, Maggioni M, Park YN, Montorsi M, Santambrogio R, Roncalli M, Bosari S.
Liver Int. 2012 May;32(5):772-82. doi: 10.1111/j.1478-3231.2012.02795.x. Epub 2012 Mar 19.

miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression.
Vaira V, Faversani A, Dohi T, Montorsi M, Augello C, Gatti S, Coggi G, Altieri DC, Bosari S.
Oncogene. 2012 Jan 5;31(1):27-38. doi: 10.1038/onc.2011.209. Epub 2011 Jun 6.

Aberrant overexpression of the cell polarity module scribble in human cancer.
Vaira V, Faversani A, Dohi T, Maggioni M, Nosotti M, Tosi D, Altieri DC, Bosari S.
Am J Pathol. 2011 Jun;178(6):2478-83. doi: 10.1016/j.ajpath.2011.02.028. Epub 2011 May 6.

Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors.
Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, Snyder E, Faversani A, Coggi G, Flavin R, Bosari S, Loda M.
Proc Natl Acad Sci U S A. 2010 May 4;107(18):8352-6. doi: 10.1073/pnas.0907676107. Epub 2010 Apr 19.

Pseudohypoparathyroidism and GNAS epigenetic defects: clinical evaluation of albright hereditary osteodystrophy and molecular analysis in 40 patients.
Mantovani G, de Sanctis L, Barbieri AM, Elli FM, Bollati V, Vaira V, Labarile P, Bondioni S, Peverelli E, Lania AG, Beck-Peccoz P, Spada A.
J Clin Endocrinol Metab. 2010 Feb;95(2):651-8. doi: 10.1210/jc.2009-0176. Epub 2010 Jan 8.

Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue.
Corbetta S, Vaira V, Guarnieri V, Scillitani A, Eller-Vainicher C, Ferrero S, Vicentini L, Chiodini I, Bisceglia M, Beck-Peccoz P, Bosari S, Spada A.
Endocr Relat Cancer. 2010 Feb 18;17(1):135-46. doi: 10.1677/ERC-09-0134. Print 2010 Mar.

Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma.
Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, Santambrogio R, Torzilli G, Vaira V, Pellegrini C, Roncalli M, Coggi G, Bosari S.
BMC Cancer. 2009 Apr 27;9:125. doi: 10.1186/1471-2407-9-125.

Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis.
Romagnoli S, Fasoli E, Vaira V, Falleni M, Pellegrini C, Catania A, Roncalli M, Marchetti A, Santambrogio L, Coggi G, Bosari S.
Am J Pathol. 2009 Mar;174(3):762-70. doi: 10.2353/ajpath.2009.080721. Epub 2009 Feb 13.

Regulation of survivin expression by IGF-1/mTOR signaling.
Vaira V, Lee CW, Goel HL, Bosari S, Languino LR, Altieri DC.
Oncogene. 2007 Apr 26;26(19):2678-84. Epub 2006 Oct 30.

Up-regulation of focal adhesion kinase in non-small cell lung cancer.
Carelli S, Zadra G, Vaira V, Falleni M, Bottiglieri L, Nosotti M, Di Giulio AM, Gorio A, Bosari S.
Lung Cancer. 2006 Sep;53(3):263-71. Epub 2006 Jul 13.

Carcinosarcoma of the colon: report of a case with morphological, ultrastructural and molecular analysis.
Ambrosini-Spaltro A, Vaira V, Braidotti P, Rovati MP, Ferrero S, Bosari S.
BMC Cancer. 2006 Jul 12;6:185.

EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.
Destro A, Ceresoli GL, Falleni M, Zucali PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V, Alloisio M, Rizzi A, Bosari S, Roncalli M.
Lung Cancer. 2006 Feb;51(2):207-15. Epub 2005 Dec 27.

INGM researches are supported by